Tenofovir vs entecavir

Common Questions and Answers about Tenofovir vs entecavir

truvada

another important test is precore/bcp mutants test, adefovir, lamivudine and entecavir mutants test and genotype test if you have no precore/bcp mutants your hbeag positive status will have 16% hbv clearance with the use of tenofovir plus entecavir, 24% tenofovir plus entecavir plus interferon.
guideline has made treatment failure with entecavir and tenofovir monotherapy when hbvdna has not reached und by 1 year, your doctor has made a mistake and you might be exposed to etv resistance.
Hi all, A report about tenofovir. Should HBVers change to entecavir and if yes what is the long term safety for entecavir ? Please adivse Link : http://www.hivandhepatitis.
5 people experienced serious adverse events, including 3 ALT flares during the entecavir monotherapy phase. Neutropenia (0% vs 23%) and thrombocytopenia (0% vs 8%) were significantly more common in the add-on group compared with the monotherapy group; no one in either arm developed anemia. 2 people developed severe neutropenia while on pegylated interferon.
potent antivirals like tenofovir and entecavir can make response despite only 3 years of hbvdna suppression and high hbsag.
//www.medhelp.org/posts/Hepatitis-B/gilead-trl7-agonist-and-others-already-marketed/show/1685432#post_8125376 http://www.medhelp.org/posts/Hepatitis-B/gilead-trl7-agonist-and-others-already-marketed/show/1685432#post_8132560 http://www.medhelp.
Patients were treated with NAs therapy (lamivudine, adefovir, telbivudine, entecavir and tenofovir) for at least 2 years. qHBsAg was performed every 6 months. Results Our results showed a significantly greater qHBsAg decline after 2 years in patients treated with tenofovir (0.45 logIU/ml) than in patients treated with telbivudine (0.12 logIU/ml; P < 0.001).
Well you can try Tenofovir and see how you tolerate it. It supposed to be slightly better then Entecavir - meaning more potent. If you have issues with TDF (Viread) then stop and try Baraclude. They are very comparable group of drugs. With Entecavir yes it is better to take it on an empty stomach. What I do with Baraclude is I take it at night 4 -5 hours after a meal, and then I eat 8 hours after. I find it best to keep me functional. p.s. you don't mention about your labs btw.
Thirdly, my doctor says it's pretty much a flip of the coin to decide whether to go with Baraclude(entecavir) or Viread(tenofovir). There seems to be very little data about the success rate of either. Can anyone please help me to decide which route to take? For example, comparison of side-effects, success rate(i guess that means sero-conversion) in asians, etc. And finally, how much of a difference would it make if I start treatment now or in, say, 6 months?
Patients were treated with NAs therapy (lamivudine, adefovir, telbivudine, entecavir and tenofovir) for at least 2 years. qHBsAg was performed every 6 months. Results Our results showed a significantly greater qHBsAg decline after 2 years in patients treated with tenofovir (0.45 logIU/ml) than in patients treated with telbivudine (0.12 logIU/ml; P < 0.001).
htm International patients have a link as well. U.S. CLINICAL TRIALS FOR CHRONIC HBV NEW! - Tenofovir Alone vs. Tenofovir with Emtricitabine for CHB Test whether the combination of two medications, tenofovir and emtricitabine, are safer and more effective for treating CHB than tenofovir alone. Contact: Patient Recruitment and Public Liaison Office (800) 411-1222 or ***@**** (Study ID# 07-DK-0207 / Identifier - NCT00524173). NEW!
i am checking all pros and cons about entecavir/tenofovir combo vs entecavir mono for me and in general for all. i am probably in cirrhosis or early cirrhosis and doctor put me in etecavir mono because of tenofovir kidney problems and possible discontinuation of tx but: checking tenofovir trials on hbv only (no hiv coinfection) kidney problems are in less than 1% patients and i haven't found tx discontinuation because of kidney problems.
Notably, just 2% of combination entecavir/tenofovir recipients and 3% of entecavir monotherapy recipients experienced serum creatinine increases (≥ 0.3 mg/dL), a possible indicator of kidney impairment, which is a potential toxicity of tenofovir. http://www.hivandhepatitis.
HBeAg seroconversion was also less likely in the entecavir/tenofovir arm (22% vs 33%). Virological breakthrough occurred in 4% of entecavir/tenofovir recipients and 1% of entecavir monotherapy recipients. However, no entecavir or tenofovir drug resistance mutations were detected in either arm Maybe Potent A + Potent B is not twice the potency and barrier to resistance. I don't know.
at this point the best choice would be tenofovir which is much cheaper and much potent with no resistance detected until now, also nitazoxanide should work preventing resistance but i don t suggest that for this purpose since we only have in vitro studies and no in vivo trials about prevention of resistance tenofovir has also a generic called tenvir (about 99usd), tenofovir is also sold at about 10usd or less per bottles in poor asian countries where the generic tenvir is taking all the market
so your friend should have start with tenofovir from the begining as guidelines say now luckily at the end of all this mess on 2008/2009 guidelines only tenofovir can be used as first line therapy and entecavir only in naive patients.
Medication (see also Medication, below) Currently, interferon alfa (IFN-a), lamivudine, telbivudine, adefovir, entecavir, and tenofovir are the main treatment drugs approved globally, although ongoing trials are investigating new types of medications, such as tenofovir disoproxil in combination with emtricitabine, clevudine (l-FMAU), and therapeutic vaccines. It appears that lamivudine and telbivudine are not recommended as first-line agents in the treatment of hepatitis B disease.
These compounds are other nuceloside analogs, variants, as so many exist, that act principally like Tenofovir or Entecavir. The chance for any one of those to achieve practical standing at this time of historical development is extremely small. The only drug currently in advanced development with a very realistic chance to join the established very selected antiviral HBV drug family is the following.
Current treatment comprised lamivudine (1pt.), lamivudine plus adefovir (2pts.), entecavir (7pts.), or entecavir plus tenofovir (2pts.). Mean baseline HBs-Ag accounted for 4,695 (range 16-15,120) IU/ml. HBV viral load was below limit of detection ( 6 months. Results: During add-on therapy, in 2 patients a continuous decline of quantitative HBsAg by -2,6log10 and -3,66 log10 was observed at week 32 and 36, respectively. The decline became detectable from week 8 and 16 on, resp.
only 3 years on entecavir vs other patients 6-8 years hbsag was about 7800iu/ml on entecavir patient he had a big decrease of hbsag all of a sudden and also had the best off therapy response keeping low hbsag, i think this patient will seroconvert in a couple of years or just by another interferon course, not to menthion the possibility to add alinia to improve svr
Morphometric measurements of livers from surviving cirrhotic animals and controls (n = 5 each) showed that mean hepatocyte mass was maintained in the cirrhotic livers [cirrhosis (17.0 ± 2.0) vs. controls (13.9 ± 0.9 gm)]. The galactose breath test was also maintained, whereas the aminopyrine breath test was significantly decreased in the surviving cirrhotics. The galactose breath test, but not the aminopyrine breath test, correlated with hepatocyte mass (r = 0.67).
However, if patients are being treated with a drug that has a low rate of resistance development, such as entecavir, they can continue treatment to and beyond 48 weeks. In this situation, patients should undergo serum HBV DNA testing every 3 to 6 months. Some drugs, such as adefovir, have a delayed antiviral effect. These patients should remain on therapy but be monitored every 3 months, with further assessment after 48 weeks of therapy.
by the way i also checked hbsag seroconvertion rates with all antivirals, adefovir in monotx as almost 0% chances of seroconvertion (natural seroconvertion is 1-2% per year), so the best combo chances with alinia are probably with 3, 2 and 1, theoretically alinia is also the best combo the prevent resistance since it works against all resistant strains and has no resistance 1 Entecavir 5,1% 2 tenofovir 6% 3 tenofovir+ftc 10,3% per year (early data on hiv coinfected pati
you can also add that hbv clearance on hbeag positive is irrelevant on entecavir and 16% on tenofovir at 3years, so entecavir is a total failure also in clearance rates in your case the highest clearance was on tenofovir+peginterferon like gmr treatment, it reached 24% hbv clearance in ashort time, dont remember if 6 or 12 months, this 24% could rise much more in personalized hbsag tdf+pegintf long term treatment like tdf+pegintf for 2 years or more
sorry i cannot read all post now but i have to anser to such a moron, only entecavir and tenofovir can be used safely as hbv monotherapy, that is all, plus why use a weak drug since we have more potent you can judge the doctor yourself and wonder if he has any pay back from drug makers or distributors about prescribing a dead market drug, i don t say he is stupid because it cannot be
entecavir can be used safely even with severe kidneys disease since it has no impact on kidneys function you can safely lower tenofovir splitting pills and start combo with entecavir after about 3 months you can stop tenofovir complitely.also consider that etv is more potent than tnf on hbsag are you also making combo with ntz? i also suggest to take coq10 200mg and nac 2.
Doctor asked to take Lamuvir, absolutely do not take that drug, the only firstline drugs are tenofovir, entecavir, interferon.
May I ask the reason for Adevori + Lumuvudine combo treatment? Is it correct entecavir + tenofovir are stronger in potency against resistance?
MedHelp Health Answers